We are actively seeking investors to help bring these life-saving drugs to market.
What we are seeking.
We have completed three* of the four FDA requirements to get our drug certified and approved as an Investigational New Drug. We are seeking investment funding to get to the last and most expensive stage of FDA Pre-Clinical development: (ADMET & PK—Absorption, Distribution, Metabolism, Excretion, Toxicology, & Pharmacokinetics of the drug in the body).
*The three FDA stages we've already completed:
1. Analytical Method Development
2. Efficacy
3. Large -Scale Process Development
Our ultimate goal.
Completing the ADMET & PK stage takes approximately 24-30 months, and our ultimate goal is to out-license the drug for Parkinson's disease indication to a large Pharmaceutical buyer in return for up-front, milestones' and royalties' fees respectively.
A few stats on Parkinson’s Disease.
Nearly one million people in the U.S. are living with Parkinson's disease (PD). This number is expected to rise to 1.2 million by 2030. PD is the second-most common neurodegenerative disease after Alzheimer's disease. 90,000 people in the U.S. are diagnosed with PD every year. The combined direct and indirect cost of PD, including treatment, social security payments and lost income, is estimated to be nearly $52 billion per year in the U.S. alone. Medications alone cost an average of $2,500 a year and therapeutic surgery can cost up to $100,000 per person. The global PD market which was $2.8 billion in 2022, will rocket up to $5.66 billion by 2030.